IT Trailblazers Step Into The Spotlight With 2025 Jumpies Award

LOUISVILLE, Colo., Jan. 29, 2025 (GLOBE NEWSWIRE) — JumpCloud Inc. has revealed the distinguished winners of the 2025 JumpCloud customer awards, the Jumpies. The Jumpies honors customers' innovative solutions using JumpCloud across three categories, including: Best Use Case: Customers that use JumpCloud to transform their business in a mission-critical way. Scaling for Success: Customers that […]

Fiverr to Release Fourth Quarter and Full Year 2024 Results on February 19, 2025

(NYSE:FVRR), NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) — Fiverr International Ltd. (NYSE: FVRR), the company that is changing how the world works together, today announced it will release fourth quarter and full year financial results for the period ended December 31, 2024, before the market opens on Wednesday, February 19, 2025. On that day

Champions of The Channel: Announcing JumpCloud’s 2024 Partner Award Winners

LOUISVILLE, Colo., Jan. 29, 2025 (GLOBE NEWSWIRE) — JumpCloud Inc. is proud to announce the winners of its inaugural Partner Awards program. The program recognizes and celebrates the outstanding contributions of partners across both managed service provider (MSP) and value-added reseller (VAR) categories. The 2024 awards honor top performers in major global regions, with a

NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference

(NasdaqGM:NAMS),(NasdaqGM:NAMSW), NAARDEN, The Netherlands and MIAMI, Jan. 29, 2025 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or

Greif Announces Strategic Actions

(NYSE:GEF),(NYSE:GEF.B),(NYSE:GEF-B), DELAWARE, Ohio, Jan. 29, 2025 (GLOBE NEWSWIRE) — Greif (NYSE: GEF, GEF.B), a global leader in industrial packaging products and services, announced today it will permanently cease production on the Number 1 Paperboard Machine (A1) in Austell, GA and permanently close the containerboard and uncoated recycled paperboard (URB) mill in Fitchburg, MA. “Decisions like

GCM Grosvenor to Present at the Bank of America Securities Financial Services Conference on February 12, 2025

(NasdaqGM:GCMG), CHICAGO, Jan. 29, 2025 (GLOBE NEWSWIRE) — GCM Grosvenor (Nasdaq: GCMG), a global alternative asset management solutions provider, will present at the Bank of America Securities Financial Services Conference on Wednesday, February 12, 2025, at 2:40 p.m. ET. A link to the live audio webcast of the presentation is available on GCM Grosvenor's public

VoIP-Pal Files Amended Complaint in Class Action Lawsuit, Expands Claims to Include RICO and Add Deutsche Telekom as a Defendant

(Other OTC:VPLM),(OTC US:VPLM), WACO, Texas, Jan. 29, 2025 (GLOBE NEWSWIRE) — VoIP-Pal.com Inc. (“VoIP-Pal,” “Company”) (OTCQB: VPLM) has filed an amended complaint in its ongoing Class Action lawsuit (CIVIL ACTION NO. 1:24-cv-03054-RDM) against major telecommunications providers, including AT&T, Verizon, and T-Mobile. The amended filing expands the scope of claims and includes additional defendants, highlighting significant

EllisDon Announces the Appointment of Melissa Chee to its Board of Directors

Mississauga, ON, Jan. 29, 2025 (GLOBE NEWSWIRE) — EllisDon Corporation announces the appointment of Melissa Chee to its Board of Directors. A visionary technology executive, entrepreneur, and business leader, Chee brings over 25 years of diverse experience scaling global technology multinationals and start-ups, while fostering innovation and inclusion in the tech ecosystem.    “Melissa's appointment to

Dewpoint Therapeutics Announces DPTX3496 as a Development Candidate for the Treatment of Colorectal, Breast, and Lung Cancers

Dewpoint Therapeutics' second development candidate, DPTX3496 is an oral, small molecule acting via a novel condensate-modulating mechanism of action for the treatment of Wnt-driven cancers DPTX3496 shows robust tumor regression and stasis in pre-clinical animal models of colorectal, breast, and lung cancer DPTX3496 is currently in IND-enabling studies and IND filing is planned for the

aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

(NASDAQ:ATYR), Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT(TM) study of efzofitimod in pulmonary sarcoidosis; topline data from the study expected in the third quarter of 2025 Current epidemiology and treatment practices for pulmonary sarcoidosis in the U.S. based on real-world evidence SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) — aTyr Pharma,

Scroll to Top